🕵️ X4 Pharmaceuticals, Inc ($XFOR)
SEC insider & ownership activity, last 12 months · CIK 1501697 · every row links its SEC filing
Over the last 12 months insiders sold $429K against $250K of open-market buying. Adam R. Craig bought $250K in discretionary trades (Oct–Aug). Scott D. Sandell trimmed 10.0% → 6.2%; Ali Behbahani trimmed 10.0% → 6.2%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $250K (1 lots) · 3 sellers, $429K (4 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Adam R. Craig | 1 | $250K | 1 | $211K | Aug 12, 2026 |
| Kirske David | 0 | – | 2 | $109K | Jun 30, 2026 |
| Volpone John | 0 | – | 1 | $109K | Aug 12, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Morgan Stanley | 10.2% | 13G | Mar 6, 2026 | filing ↗ | |
| Morgan Stanley Investment Management Inc. | 10.2% | 13G | Mar 6, 2026 | filing ↗ | |
| Coastlands Capital LP | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Coastlands Capital Partners LP | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Coastlands Capital GP LLC | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Coastlands Capital LLC | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Matthew D. Perry | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Coastlands Capital LP | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| Matthew D. Perry | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| Coastlands Capital Partners LP | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| Coastlands Capital LLC | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| BAIN Capital Life Sciences Fund II, L.P. | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| BCLS II Investco, LP | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| BCIP Life Sciences Associates, LP | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| BAIN Capital Life Sciences Fund, L.P. | 10.0% | 13D | Aug 11, 2025 | filing ↗ | |
| Empery Asset Management, LP | 10.0% | 13G | Jan 15, 2026 | filing ↗ | |
| Ryan M. Lane | 10.0% | 13G | Jan 15, 2026 | filing ↗ | |
| Ryan M. Lane | 10.0% | 13G | Oct 21, 2025 | filing ↗ | |
| Martin D. Hoe | 10.0% | 13G | Oct 21, 2025 | filing ↗ | |
| FMR LLC | 9.7% | 13G | Feb 5, 2026 | filing ↗ | |
| Abigail P. Johnson | 9.7% | 13G | Feb 5, 2026 | filing ↗ | |
| DEEP Track Capital, LP | 8.3% | 13G | Aug 14, 2026 | filing ↗ | |
| David Kroin | 8.3% | 13G | Aug 14, 2026 | filing ↗ | |
| Perceptive Advisors LLC | 8.1% | 13G | Aug 14, 2026 | filing ↗ | |
| Joseph Edelman | 8.1% | 13G | Aug 14, 2026 | filing ↗ | |
| Perceptive Life Sciences Master Fund, Ltd. | 8.1% | 13G | Aug 14, 2026 | filing ↗ | |
| BCLS II Equity Opportunities, LP | 7.4% | 13G | Feb 17, 2026 | filing ↗ | |
| Saturn V Capital Management LP | 7.4% | 13G | Feb 17, 2026 | filing ↗ | |
| Xiaoying Tian | 7.4% | 13G | Feb 17, 2026 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 7.2% | 13G | Aug 14, 2026 | filing ↗ | |
| Scott D. Sandell | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Ali Behbahani | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Carmen Chang | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Edward T. Mathers | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Anthony A. Florence, JR. | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Mohamad H. Makhzoumi | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| NEA 18 Venture Growth Equity, L.P. | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| NEA Partners 18 VGE, L.P. | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| NEA 18 VGE GP, LLC | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Paul Walker | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| Rick Yang | 6.2% | 13D | Oct 27, 2025 | filing ↗ | |
| BlackRock, Inc. | 5.9% | 13G | Jul 30, 2026 | filing ↗ | |
| Trails EDGE Capital Partners, LP | 5.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Trails EDGE Biotechnology Master Fund, LP | 5.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Ortav Yehudai | 5.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Inception Trust | 5.2% | 13G | Mar 6, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| John Volpone | $112K | Aug 12, 2026 | filing ↗ |
| Adam Craig | $216K | Aug 12, 2026 | filing ↗ |
| David Kirske | $73K | May 12, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Other events (8.01) | Sep 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 8, 2026 | filing ↗ |
| Other events (8.01) | Sep 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 8, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 30, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 30, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 11, 2026 | filing ↗ |
| Shareholder vote (5.07) | May 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 11, 2026 | filing ↗ |
| Shareholder vote (5.07) | May 11, 2026 | filing ↗ |
| Earnings (2.02) | Nov 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 5, 2025 | filing ↗ |
| Material agreement (1.01) | Oct 23, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 23, 2025 | filing ↗ |
| Exit or disposal costs (2.05) | Sep 15, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 15, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 15, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 15, 2025 | filing ↗ |